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Abstract
In clinical orthopaedics, total joint replacements and spinal 
fusions are routine undertakings. Many of the implicated 
patients suffer from osteoporosis, severe arthrosis or 
osteopaenia. In individuals thus afflicted, the bony bed 
lacks the mechanical stability that is a requisite for a firm 
anchorage of the implant and its functional competence. To 
promote the bony bondage of an implant it is necessary to 
induce neo-ossification by the introduction of an osteogenic 
agent, such as bone morphogenetic protein 2 (BMP-2). 
Since this growth factor is generally applied in a free form 
and at high dosages to maximise its osteogenicity, untoward 
side effects frequently ensue.
 We hypothesise that the administration of BMP-2 
using a suitable delivery vehicle, and its gradual, low dose 
release therefrom in a cell-mediated manner, would avert 
the triggering of undesired side effects and enhance its 
efficacy.
 To test this postulate, implants of porous titanium were 
coated with a layer of calcium phosphate into which BMP-2 
was biomimetically incorporated at dosages ranging from 
0.8 to 500 µg/g of coating material (delivery system) prior 
to their surgical placement in the tibiae of adult sheep. The 
volume and the surface area of newly-formed bone were 
evaluated histomorphometrically after 3 and 6 weeks. The 
highest values were achieved using BMP-2 dosages of 20 to 
100 µg/g of coating: The deposition of bone was confined 
to the immediate vicinity of the implant and was observed 
deep within the interstices of its meshwork, to the walls 
of which it bonded well. The findings of the study attest 
to the validity of our hypothesis.
Keywords: Porous titanium implants, locally-contained 
BMP-2, dosage optimisation, slow-release delivery system, 
osteoinduction, osseointegration.
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Introduction
There are many situations in clinical orthopaedics and 
dental implantology in which a tool wherewith to induce 
the neoformation of osseous tissue would be a very 
welcome alternative to the autologous transplantation of 
bone to facilitate or accelerate the healing of fractures and 
non-unions or the osseointegration of implants. One such 
potential tool is bone morphogenetic protein 2 (BMP-2). 
This osteogenic agent has been approved for clinical 
use in the context of spinal fusion, but not yet for other 
indications. Although clinical findings appertaining to 
the use of BMP-2 in spinal fusion are fairly impressive, 
the success of the procedure is often overshadowed by 
the manifestation of severe undesired side effects, which 
can seriously impair the health and the musculoskeletal 
functions of the treated patient (Faundez et al., 2016; 
James et al., 2016). These include ectopic bone formation, 
paralysis and neurological disturbances (Hofstetter et al., 
2016; Vavken et al., 2015) [but not malignant pathologies 
(Cahill et al., 2015; Malham et al., 2015)].
 BMP-2 is currently applied topically in a free 
form together with a collagenous matrix (Burkus et 
al., 2003). The recommended dosage is exceedingly 
high [e.g. 12 mg/ACS (absorbable collagen sponge), 
7.5 cm × 10 cm × 0.4 cm, 0.322 g; this corresponds to 
37.3 mg of BMP-2/g of ACS], and it is thus more than 
conceivable that therein lies the trigger for many of the 
untoward side effects (Benglis et al., 2008; Hofstetter et 
al., 2016). Many growth factors, including BMP-2, are 
known to act pleiomorphically. Whether one or another of 
the polarised effects is triggered depends critically upon 
the concentration of the agent. The induced response can, 
however, be readily reversed by a secondary adjustment 
of the dosage. BMP-2 acts osteoinductively at low 
(ng-to-µg) concentrations (Herberg et al., 2014), and 
osteolytically at high ones in the mg range (Pobloth et al., 
2015). Moreover, not only the concentration, but also the 
mode of application and the manner in which the agent is 
presented to the targeted population of progenitor cells can 
influence their response (anabolic or catabolic), as well as 
their differentiation pathway.
 We hypothesise that if BMP-2 is presented to the 
targeted area in a form that is physiomimetic, which could 
be achieved by incorporating it into a bone-matrix-like 
material, then its effects would be confined to the said 
region. However, to avoid the triggering of undesirable side 
effects, the concentration at which the agent is liberated 
from its carrier must fall within the range that is maximally 
conducive to osteogenesis and minimally promotive of 
osteolysis.
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 The purpose of the present study was to elucidate the 
BMP-2-dosage range that is optimal for bone formation. 
To this end, the agent was incorporated at different 
concentrations into calcium-phosphate (bone-matrix-like) 
coatings (delivery system), which were simultaneously 
deposited upon experimental porous meshes of titanium. 
The agent is thereby released in a cell-controlled manner 
(Hagi et al., 2010; Liu et al., 2005a; Liu et al., 2005b). The 
prostheses were implanted within the tibiae of adult sheep. 
Bone formation and osseointegration were monitored 
histomorphometrically after 3 and 6 weeks. Optimal 
outcomes were achieved using concentrations of BMP-2 
(20 to 100 µg/g of carrier) that lie very much closer to the 
intrinsic bony levels in mammals [1 to 3 ng/g of bone in 
bovine cows (Baylink et al., 1993; Wozney et al., 1988)] 
than do those that are currently applied in clinical practice 
(37300 µg/g of carrier, see above).
Materials and Methods
Porous titanium implant
For the present study, we employed an experimental 
semi-circular implant (length: 24.5 mm; width: 9.2 mm; 
thickness: 6.1 mm), which was designed and manufactured 
by Smith & Nephew (London, UK). It is comprised of a 
solid core of titanium and an overlying porous mesh of 
the same metal (Fig. 1). The confinement of the porous 
mesh to the four faces, which are cut off from one another 
by the intervening solid core, ensures that the ingrowth of 
bone from each side of the implant can be independently 
quantified. The interconnectivity of the system of pores 
assures the continuous (unimpeded) ingrowth of blood 
vessels and osseous tissue.
Biomimetic coating of the implants and the 
incorporation of BMP-2
The biomimetic coating of the implants with a layer of 
octacalcium phosphate and the simultaneous incorporation 
of BMP-2 (Inductos, Medtronic AG, Münchenbuchsee, 
Switzerland) was performed as previously described 
(Liu et al., 2005a; Liu et al., 2004; Liu et al., 2006). In 
summary, a 1 to 3 µm-thick seeding layer of amorphous 
calcium phosphate was first deposited, then a thicker 
crystalline one (20 to 50 µm), into which BMP-2 was 
simultaneously incorporated. The entire coating procedure 
was conducted under sterile conditions. In a previous study, 
BMP-2 was established to be homogeneously distributed 
throughout the coating (Liu et al., 2003). To quantify the 
incorporated amounts of the agent (Table 1), the implants 
(n = 3 for each dosage of BMP-2) were first soaked in 
0.5 M ethylenediaminetetraacetic acid (Sigma-Aldrich, St 
Louis, MO, USA) (pH 8) containing 0.1 % bovine serum 
albumin (Sigma-Aldrich, St Louis, MO, USA) to dissolve 
the coating. The amount of BMP-2 in the solution was then 
determined using the human BMP-2 ELISA development 
kit (Peprotech, Rocky Hill, NJ, USA).
BMP-2 concentrations
In a preliminary study (unpublished data), we investigated 
the influence of two different, relatively high, concentrations 
of BMP-2: 2900 µg/g of coating and 6363 µg/g of coating, 
Fig. 1. Images of the experimental titanium implant. (A) Photograph of the implant at low magnification (left) and 
scanning electron micrograph of its porous surface (right). (B) Photograph of the implant without a coating. (C) 
Photograph of the implant after the biomimetic deposition of a layer of calcium phosphate. (D) Photograph of a vertical 
section through the porous mesh of the implant after the biomimetic deposition of a layer of calcium phosphate. The 
layer of calcium phosphate was stained with 2 % Alizarin red.
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which yielded total amounts per implant of ~ 160 µg and 
~ 350 µg, respectively. These dosages are approximately 
10-fold lower than those that are currently applied in 
clinical practice (Tannoury and An, 2014). At these two 
concentrations, the resorption of bone around the implants 
was massive after 3 weeks. Hence, their effects were not 
further pursued. The dosages of BMP-2 that were tested 
in the present study ranged from 0.8 µg to 500 µg/g of 
coating; specifically, 0.8, 4, 20, 100 and 500 µg/g of 
coating (Table 1).
Animal model
For the present study, the animal model needed to be one 
with a limb size that was large enough to carry the implant 
and to furnish a sufficiency of trabecular bone to stably 
support it after insertion (sufficient primary stability). The 
proximal tibia of adult sheep satisfied these criteria.
 The sheep were handled in accordance with the UK 
Animal Act (1986) and the associated guidelines (EU 
Directive 2010/EU for animal experiments).
Surgery and anaesthesia
A total of 18 quarantined adult stock sheep were used in 
the present study. Per animal, two implants were surgically 
inserted into the proximal tibia: one on the left side and 
one on the right. The treatment groups were allocated to 
each side according to a randomisation table.
 To ascertain whether the volume of trabecular bone 
in the tibial plateau sufficed for implantation, the site was 
fluoroscopically screened prior to surgery.
 General anaesthesia was induced by intramuscular 
injections of Ketamine (Narketan, Vetoquinol UK Ltd., 
Buckingham, UK: 100 mg/mL, 10 mg/kg of body weight) 
and Xylazine (Rompun, Bayer PLC, Newbury, UK: 20 mg/
mL, 0.1 to 0.3 mg/kg of body weight), and was maintained 
with a mixture of isoflurane, oxygen and nitrous oxide. 
Buprenorphine (Buprecare, Animalcare Ltd, York, UK: 
0.3 mg/mL, 0.01 mg/kg of body weight) was administered 
as an analgesic on the day of surgery, minimally 48 h 
thereafter, and subsequently as required. Infection was 
warded off prophylactically by an intramuscular injection 
of long-acting amoxicillin (Clamoxyl L.A, Zoetis UK Ltd., 
London, UK: 150 mg/mL, 15 mg/kg of body weight) at the 
time of surgery and for the two subsequent days. Using a 
standard surgical approach, an incision was made on the 
medial side of the proximal tibia and the soft tissue was 
resected to expose its medial surface. Defects were created 
3 mm below and parallel to the medial tibial plateau. Two 
fixation-screw holes were then drilled into the bone and 
the base-plate was secured. Bony debris was removed 
by irrigation with saline solution. The implant was then 
press-fitted into the defect. After layer-by-layer closure of 
the wound, the procedure was repeated on the contralateral 
tibia. To ascertain whether the implants had been correctly 
inserted, the surgical sites were radiographed. During 
the recovery phase, the sheep were penned individually 
and observed until they had regained consciousness. The 
dermal sutures were removed either 10 to 14 d after surgery 
or as soon as healing had occurred (whichever came first).
Histomorphometry
At the end of the monitoring period, the sheep were 
killed by administering an overdose of pentobarbital. The 
hind limbs were harvested and the soft tissues removed. 
The proximal tibiae were severed from the tibial shafts 
approximately 5 cm distal to the tibial plateaus. The 
dissected proximal tibiae were chemically fixed in chilled 
10 % neutral formalin (Fisher Scientific, Loughborough, 
UK). The soft tissue was then removed from the front of 
each implant. The cutting band of an Exakt Macro Band 
saw (Exakt Technologies, Inc., Oklahoma City, OK, USA) 
was aligned with the anterior edge of the implant. The first 
sagittal cut was made at random within the first 5 mm, 
according to a systematic random sampling protocol. 
The implant was then cut into four 4 mm-thick slabs. 
The tissue slabs were immersed in 10 % neutral-buffered 
formalin for a minimum of 7 d to complete the process 
of chemical fixation. All tissue slabs were dehydrated in 
ethanol, cleared in xylene and embedded in Technovit 
7200VLC resin (Exakt Technologies, Inc., Oklahoma 
City, OK, USA). Sections were cut, ground down to a 
thickness of ~ 30 µm and then polished using the Exakt 
cutting and grinding system. Two sections per tissue slab 
were prepared. One section was stained with Alizarin Red 
(Sigma-Aldrich, St Louis, MO, USA) and the other with 
Sanderson’s rapid bone stain (Dorn & Hart Microedge, 
Inc., Loxley, AL, USA).
 The sections were examined in a Nikon Eclipse E1000 
light microscope (Nikon, Tokyo, Japan) and the two 
regions of interest identified, namely, the “mesh” space 
and the “peri-implant” space (Fig. 2A), which represent the 
reference areas for the histomorphometric analysis. Using a 
grid that conforms with established stereological principles 
(Gundersen et al., 1988), ten images per slide, eight in 
the mesh space and two in the peri-implant space, were 
captured at a final magnification of 10×. With four slides 
Table 1. BMP-2-concentration groups. Displayed are the targeted dosages/g 
of coating, the actual dosages/g of coating and the actual dosages/implant 
(mean values ± SEM; n = 3 in each case).
Target dosage of BMP-2 Actual dosage of BMP-2
 (µg/g of coating)  (µg/g of coating)  (µg/implant)
0 (Control: no BMP-2; no coating) 0 0 
0.8 0.7 ± 0.2 0.068 
4 4.7 ± 0.5 0.455 
20 18.6 ± 3.5 1.801 
100 85.2 ± 8.2 8.249 
500 478.4 ± 14.5 46.319 
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per implant, a total of 30 to 40 images were obtained per 
sample, which yielded ~ 300 to 500 point (or intersection) 
hits per parameter and per experimental group.
 For the histomorphometric analysis, three different 
methods were implemented to estimate the targeted 
parameters: Cavalieri’s method (Gundersen and Jensen, 
1987) to estimate the volumes of the reference spaces, 
the point-counting method (Cruz-Orive and Weibel, 
1990; Gundersen et al., 1988) to estimate the volume 
fraction (Vv) of the estimators in the reference space 
(Vref), and the intersection method (Baddeley et al., 1986; 
Cruz-Orive and Weibel, 1990; Gundersen et al., 1988) 
to estimate the surface density (Sv) of the estimators in 
the reference space. The estimated total volume (or total 
surface area) of each estimator was derived as the product 
of its volume fraction (Vv) [or surface density (Sv)] and 
the corresponding reference volume.
 Assuming the reference volume (mesh or peri-implant 
space) to be the same for all implants, a mean value for six 
controls was determined. Within the mesh space, the porous 
volume was derived by subtracting the titanium mesh 
volume from the total volume of the mesh space. Within 
the peri-implant space, pre-existing and neo-formed bone 
were distinguished on the basis of their different tinctorial 
properties, the former having a light red and the latter a 
dark red hue (Fig. 2B).
 Bone and coating volume fractions [Vv (bone), Vv 
(coating)] in the mesh space were defined as volume 
fractions of the mean porous space. Three native (control) 
implants were used to estimate the pre-implantation coating 
volume (time point zero). Three additional implants per 
concentration group (n = 18) were used to calculate the 
mean coating weight (mg). The implants were weighed 
with a high-precision balance before and after coating. 
The difference between the two weights gave the coating 
weight per implant. The mesh space was subdivided into 
inner and outer halves (Fig. 2A).
 The intersection method was used to estimate the 
following interfacial areas in the porous space (Fig. 3): the 
bone-surface area (red line in Fig. 3), the bone-to-coating 
interfacial area (green line in Fig. 3), the titanium-to-
coating interfacial area (yellow line in Fig. 3) and the 
titanium-to-bone interfacial area (blue line in Fig. 3). Using 
six control implants, the total surface area of the titanium 
mesh was determined. The mean value was used as the 
reference surface area of the mesh for all other implants. 
The total peri-implant space, as well as the surface areas of 
pre-existing and neo-formed bone, were also determined.
 From the measured parameters, the following 
secondary estimators were computed for each time point: 
coating thickness (µm), specific coating weight (mg/mm3 
of coating), mass of residual coating (g), mass of degraded 
coating (g), degraded coating volume [(mm3) at 3 weeks 
and 6 weeks], coating degradation rate (mm3/d), mean 
coating degradation rate [(mm3/d) over 6 weeks], uncoated 
surface area of titanium (mm2), free surface area of titanium 
[(mm2) no bone or coating], bone-to-implant contact area 
[(mm2) BIC], absolute liberated amount of BMP-2 [(µg) 
at each time point and over 6 weeks], absolute amount 
of BMP-2 in residual coating volume (µg), mean BMP-2 
release rate per day [(µg/d) at each time point and over 6 
weeks], net efficacy of BMP-2 for bone volume [(mm3 of 
neo-formed bone/µg of BMP-2) per time point and per 
reference space], net efficacy of BMP-2 for bone surface 
area [(mm2 of neo-formed bone/µg of BMP-2) per time 
point and per reference space], net bone volume produced 
(mm3) and trabecular thickness of neo-formed and pre-
existing bone (mm).
 Previous studies have revealed BMP-2 to be 
homogeneously incorporated into the coating (Liu et al., 
2004; Liu et al., 2003). Hence, the absolute amount of 
BMP-2 that is liberated is proportional to the amount of 
the coating that is degraded. Consequently, the absolute 
amount of liberated BMP-2 can be estimated from the 
Fig. 2. (A) Low-magnification light micrograph of an implanted implant and (B) a higher-magnification view of 
the peri-implant space. (A) Histological image of a transverse section through an implant (black) after its insertion 
into the proximal tibial bone (Tb.B), illustrating the two reference spaces: the mesh space (boxed in yellow) and the 
peri-implant space (boxed in blue). Lengthwise, the peri-implant space had common borders with the implant; width- 
wise, it was defined to extend half of the distance (d/2) of the mesh space (d). (B) Histological image of a transverse 
section through the peri-implant space, illustrating the different tinctorial properties of pre-existing [(old) O. B.] and 
neo-formed bone (N.B.). WAT: white adipose tissue.
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degraded coating volume. According to the same premise, 
it is possible to estimate the amount of BMP-2 that is 
retained by the residual coating at the 3- and 6-week 
junctures.
 Net BMP-2 efficacy was defined as the net volume of 
bone that was formed per microgram of liberated BMP-2 
per time point. Net bone volume was calculated as the total 
bone volume minus the corresponding mean bone that was 
estimated in the implanted control. Gross BMP-2 efficacy 
was calculated as the absolute volume of bone that was 
deposited within the reference space per microgram of 
liberated BMP-2 per time point. All BMP-2 efficacies were 
calculated for both the mesh and the peri-implant spaces.
 The bone-to-implant contact area (BIC), which is 
relevant for the implant-fixation strength and therefore for 
osseointegration, was defined as the surface area that is in 
direct contact with the titanium mesh (titanium-to-bone 
interfacial area) plus the indirect bone-to-titanium contact 
area [with an intervening layer of coating (Fig. 3)].
Statistics
All data are presented as mean values together with the 
standard error of the mean (SEM). Differences between the 
groups were analysed using the one-way ANOVA test. The 
level of significance was set at p < 0.05. SPSS statistical 
software (SPSS Inc., Chicago, IL, USA, version 16 for Mac 
Os X) was used for the statistical calculations. Dunnett’s 
two-sided post hoc test was implemented to compare the 
data in the control and the experimental groups.
Results
Basic implant data
To estimate the reference volumes, namely, the volume of 
the titanium mesh and that of the peri-implant space, as 
well as the surface area of the mesh, six control implants 
(n = 6) were analysed. The volume of the peri-implant 
space was estimated 3 and 6 weeks after surgical prosthetic 
placement. The volume and the surface area of the mesh 
were estimated prior to implantation (time point zero) 
and 3 weeks later. The implantation process per se had no 
influence on either the volume or the surface area of the 
mesh. The analyses revealed the mean volumes of the mesh 
and the peri-implant spaces to be 378.5 ± 7.4 mm3 and 
194.2 ± 3.8 mm3, respectively (Table 2). The mean volume 
of the porous space in the mesh space was 250.9 ± 6.1 mm3, 
with a volume fraction of 66.3 ± 1.0 %. The intersection 
analysis of the mesh revealed its total surface area to be 
2093.2 ± 28.0 mm2 per implant (Table 2).
Coating data at time point zero
The analysis of the three unimplanted controls revealed 
the mean coating volume to be 98.2 ± 6.2 mm3, with 
F i g .  3 .  S c h e m a t i c 
r ep re sen ta t ion  o f  t he 
i n t e r f a c e s  t h a t  w e r e 
recognised in the mesh 
space of a titanium implant. 
The total surface area of 
neo-formed bone that was 
deposited along each of these 
interfaces was estimated 
histomorphometrically. Red 
line: bone-surface area; 
green line: bone-to-coating 
interfacial area; yellow 
line: titanium-to-coating 
interfacial area; blue line: 
titanium-to-bone interfacial 
area.
Mean SEM CE (%)
Reference volume of the mesh space (mm3) 378.5 ± 7.4 2.0
Reference volume of the peri-implant space (mm3) 194.2 ± 3.8 1.9
Volume of titanium in the mesh space (mm3) 127.6 ± 4.6 3.6
Volume of the porous space (mm3) 250.9 ± 6.1 2.4
Volume fraction of titanium (%) 33.7 ± 1.0 2.9
Volume fraction of the porous space (%) 66.3 ± 1.0 1.5
Surface area of titanium (mm2) 2093.2 ± 28.0 1.3
Table 2. Histomorphometric data appertaining to various stereological estimators in the 
control implants (no BMP-2; no coating) prior to their surgical placement (time point = 0). 
n = 6 in each case. CE: coefficient of error.
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95.7 ± 0.7 % coverage of the total (inner and outer) porous 
titanium surface (Table 3). Hence, 2031.2 ± 40.2 mm2 of 
the total surface area (2093.2 ± 28.0 mm2) were completely 
covered with coating material, yielding a mean specific 
coating weight of 0.99 ± 0.06 mg/mm3 of coating (Table 
2 and Table 3). The mean thickness of the entire coating 
(amorphous and crystalline layers) was 48.3 ± 3.0 µm. 
The coating weight that was measured for the 18 implants 
prior to their surgical placement ranged from 77.3 mg to 
105.1 mg, with an overall mean of 96.8 ± 1.4 mg [CE 
(coefficient of error) = 1.5 %](Table 3).
Coating volumes 3 and 6 weeks after implant 
placement
At time point zero (unimplanted control), the coating 
volume was 98.2 ± 6.2 mm3 (Table 3). During the ensuing 
3 weeks, the degree to which the coating was degraded 
tended to increase in parallel with the rise in BMP-2 
concentration (Fig. 4). At the lowest concentration 
of BMP-2 (0.8 µg/g of coating), the residual coating 
volume at the 3-week juncture was 65.6 ± 1.8 mm3; the 
corresponding value at the second highest one (100 µg/g 
of coating) was 39.7 ± 11.3 mm3. Hence, the reduction in 
coating volume was 60.6 % higher in the latter instance 
than in the former. At the highest concentration of BMP-
2 (500 µg/g of coating), the residual coating volume was 
2.4 ± 0.5 mm3, viz., 2.5 % of the initial value. At the 6- week 
juncture, the coating-degradation activity did not follow 
a dose-dependent trend; not, at least, below a BMP-2 
concentration of 100 µg/g of coating (Fig. 4).
BMP-2 concentrations
The dosages of BMP-2 that were actually achieved (µg/g 
of coating) corresponded well with the targeted ones 
(Table 1). The actual values were used to calculate the total 
amount of BMP-2 per implant (Table 1). In the preliminary 
study that was alluded to in the Materials and Methods 
section, the total amounts of BMP-2 per implant (160 µg 
and 350 µg), were 3- to 7.5-fold higher than the highest 
one in the present study (46.3 µg, Table 1).
BMP-release kinetics
Generally speaking, most of the coating-incorporated 
depot of BMP-2 was released during the first 3 weeks 
of implantation (Fig. 5A). However, at the lowest 
concentration of BMP-2 (0.8 µg/g of coating), this was 
not the case, the released amounts being 0.02 ± 0.001 µg 
and 0.05 ± 0.004 µg at the 3- and 6-week junctures, 
respectively. By contrast, at a BMP-2 concentration 
of 100 µg/g of coating, the corresponding values were 
4.9 ± 1.0 µg and 6.9 ± 0.3 µg, respectively. Hence, at 
concentrations of 0.8 µg/g of coating and 100 µg/g of 
coating, the amount of BMP-2 that was released at each 
of the two time points differed by 51.1 % and 27.8 %, 
respectively. The increase in the (mean) absolute released 
amount of BMP-2 correlated very closely with the loaded 
dosage at each time point (ρ3w = 0.99; ρ6w = 0.99).
 The aforementioned observation was confirmed by 
calculating the BMP-2-release rates per day for the first 3 
weeks and the second 3 weeks (Fig. 5B). The correlation 
coefficient for the first 3-week period was 0.99; that for 
the second was likewise 0.99 if the data appertaining to 
the highest concentration of BMP-2 (500 µg/g of coating) 
were excluded; if they were included, it was 0.5.
Table 3. Histomorphometric data appertaining to various coating parameters in 
the experimental implants prior to their surgical placement (time point = 0). The 
estimations were made on three implants that were reserved specifically for these 
calculations.*: Average weight of 18 implants (including those that were placed 
in the animals). CE: coefficient of error.
Mean SEM CE (%)
Volume of coating (mm3) 98.2 ± 6.2 6.3
Coated surface area of titanium (mm2) 2031.2 ± 40.2 2.0
Uncoated surface area of titanium (mm2) 90.3 ± 14.3 15.9
Coated surface-area fraction of titanium (%) 95.7 ± 0.7 0.7
Uncoated surface-area fraction of titanium (%) 4.26 ± 0.7 15.8
Thickness of coating (µm) 48.3 ± 3.0 23.0
Weight of coating* (mg) 96.8 ± 1.4 1.5
Specific weight of coating (mg/mm3 of coating) 0.99 ± 0.06 6.00
Fig. 4. Residual coating volumes 3 and 6 weeks after 
implant placement (mean values ± SEM; n = 3 in 
each case). The asterisks denote the level of statistical 
significance (** p < 0.01) of comparisons with the pre-
implantation control.
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Fig. 5. BMP-2 release from the implants. (A) Absolute amounts of BMP-2 (µg) that were released 3 and 6 weeks after 
implant placement represented on a logarithmic scale (mean values ± SEM; n = 3 in each case). The percentage of 
BMP-2 that was released in each group is indicated above the corresponding column. (B) Daily release rates of BMP-
2, 3 and 6 weeks after implant placement, represented on a decadal logarithmic scale (mean values ± SEM; n = 3 in 
each case). (C) Daily release rates of BMP-2, averaged over the 6-week monitoring period, represented on a decadal 
logarithmic scale (± SEM; n = 6 in each case).
Fig. 6. Volumes of neo-formed bone. (A) Volumes of neo-formed bone in the porous space of the titanium mesh and 
(B) volumes of neo-formed and pre-existing bone in the peri-implant space 3 and 6 weeks after implant placement 
(mean ± SEM; n = 3 in each case). The asterisks denote the level of statistical significance (** p < 0.01) of comparisons 
with the control at each time point.
 The mean BMP-2-release rate per day for the entire 
6-week monitoring period was very closely and almost 
linearly related to the concentration of the agent (µg/g of 
coating) [ρ = 0.99 (Fig. 5C)].
Bone volume in the porous space of the titanium 
mesh
Somewhat surprisingly, at all BMP-2 concentrations except 
the highest one (500 µg/g of coating), the volumes of neo-
formed bone in the porous space of the titanium mesh were 
comparable at both the 3- and the 6-week junctures and did 
not differ significantly from the control values (Fig. 6A). 
At the highest tested concentration, the bone volume was 
significantly lower at the 3-week juncture [7.9 ± 2.9 mm3; 
p = 0.006], and higher, albeit not significantly, at the 6- 
week one (124.7 ± 18.2 mm3; p = 0.144) (Fig. 6A). The 
lower volume of osseous tissue at the 3-week juncture 
can be accounted for by a tip in the balance between bone 
formation and bone resorption activity towards the latter, 
which is a well-known response to high concentrations of 
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BMP-2 (Herberg et al., 2014). By the 6th week, the local 
concentration of BMP-2 had dropped to a level at which 
the balance between bone formation and bone resorption 
activity favoured the former process. These explanations 
are borne out by the images in Fig. 7. The absence of 
staining in the porous as well as in the peri-implant space 
at the 3-week juncture (Fig. 7A) attests that not only neo-
formed but also pre-existing bone had been resorbed. At 
the 6-week juncture, staining for bone is observed in both 
spaces (Fig. 7B).
Neo-formed and pre-existing bone volumes in the 
peri-implant space
In the peri-implant space, the pattern of bone formation 
and resorption was similar to that in the porous one (Fig. 
6B). The volumes of total and neo-formed bone were 
comparable to each other and to the control values at 
both the 3- and the 6-week junctures at all concentrations 
of BMP-2 except the highest one (500 µg/g of coating). 
However, the volume of pre-existing bone at the 3-week 
juncture tended to decrease with an increase in BMP-2 
concentration, although the difference attained statistical 
significance only at the highest dosage (p = 0.001). At the 
6-week juncture, no such trend was observed, except at 
the highest BMP-2 concentration, and the difference was 
statistically significant (p = 0.001) (Fig. 6B).
Bone surface area in the porous space of the titanium 
mesh
At the 3-week juncture, the surface area of neo-formed 
bone in the porous space of the titanium mesh tended to be 
higher than that in the control at all BMP-2 concentrations 
except the highest one (500 µg/g of coating) (Fig. 8A). 
However, the increase attained statistical significance only 
at dosages of 0.8 µg/g of coating (p = 0.02) and 20 µg/g 
of coating (p = 0.02). At the highest concentration of 
BMP-2, the surface area of neo-formed bone tended to be 
lower than that in the control, but the difference was not 
statistically significant (p = 0.1). At the 6-week juncture, the 
surface area of neo-formed bone was tendentially higher 
than that in the control group at all BMP-2 concentrations 
(significantly so except at 4 µg/g of coating) (Fig. 8A).
Neo-formed and pre-existing bone surface areas in 
the peri-implant space
In the peri-implant space, the surface area of neo-formed 
bone at the 3-week juncture was significantly higher (than 
that in the control) at the three lower BMP-2 concentrations 
(0.8 µg/g of coating, p = 0.001; 4 µg/g of coating, p = 0.002; 
20 µg/g of coating, p = 0.009), but not at the two higher 
ones (100 µg/g of coating, p = 0.12; 500 µg/g of coating, 
p = 0.48) (Fig. 8B). At the 6-week juncture, the surface area 
of neo-formed bone did not differ significantly from that 
in the control group at any of the BMP-2 concentrations. 
At the 3-week juncture, the surface area of pre-existing 
bone did not differ significantly from that in the control 
group at any of the BMP-2 concentrations except the 
highest one, in which case it was lower (p = 0.02). At the 
6-week juncture, the surface area of pre-existing bone was 
significantly lower than that in the control group at the 
two highest BMP-2 concentrations (100 µg/g of coating, 
p = 0.03; 500 µg/g of coating, p = 0.001).
Trabecular thickness of bone in the porous space of 
the titanium mesh
At the 3-week juncture, the trabeculae of neo-formed bone 
in the porous space of the titanium mesh were significantly 
thinner than those in the control and of comparable values 
at all BMP-2 concentrations (Fig. 9A). At the 6-week 
juncture, the trabeculae of neo-formed bone were likewise 
significantly thinner than those in the control, and likewise 
of comparable values, at all BMP-2 concentrations except 
the highest one, in which case no difference was observed 
(p = 0.110).
Fig. 7. Histological images of transverse sections through titanium implants upon which had been deposited a layer of 
calcium phosphate bearing a BMP-2 concentration of 500 µg/g of coating (A) 3 and (B) 6 weeks after their insertion 
into the proximal tibial bone. (A) At the 3-week juncture, the resorption of bone outweighed its formation in both 
the mesh and the peri-implant spaces, as evidenced by the lack of staining for osseous tissue. (B) By the end of the 
6th week, the balance between bone resorption and bone formation had been tipped in favour of the latter process.
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Trabecular thickness of neo-formed and pre-existing 
bone in the peri-implant space
In the peri-implant space, the thickness of the new bony 
trabeculae did not differ significantly from that in the 
control at any of the BMP-2 concentrations, either at the 
3- week or at the 6-week juncture (Fig. 9B). The trabeculae 
of pre-existing bone tended to be thinner than those in the 
control at the 3-week juncture, but the difference attained 
statistical significance only at BMP-2 concentrations 
of 4 µg/g of coating (p = 0.04) and 500 µg/g of coating 
(p = 0.005) (Fig. 9C). By the end of the 6th week, the mean 
thickness of the pre-existing bony trabeculae did not differ 
significantly from that in the control at any of the tested 
BMP-2 concentrations.
Bone-to-implant contact area (BIC)
The total bone-to-implant contact area [direct bone-to-
implant contact area plus indirect bone-to-implant contact 
area (with an intervening layer of coating)] at each of the 
two time points (3 and 6 weeks) increased relative to that 
in the controls (234.8 ± 18.5 mm2 and 313.3 ± 47.6 mm2, 
respectively) at all BMP-2 concentrations except the 
highest one (500 µg/g of coating) (Fig. 10 and Table 4), 
and the dose-dependent patterns were comparable at each 
juncture. At the 3-week juncture, the highest value was 
attained at a BMP-2 concentration of 0.8 µg/g of coating 
(922.6 ± 55.2 mm2, p < 0.01), viz., at the lowest dosage, 
followed by that at 20 µg/g of coating (795.1 ± 92.2 mm2, 
p < 0.01) (Fig. 10). The increases relative to the control 
Fig. 8. Bone surface area. (A) Surface areas of bone in the porous space of the titanium mesh 3 and 6 weeks after 
implant placement (mean values ± SEM; n = 3 in each case). The asterisks denote the levels of statistical significance 
(* p < 0.05; ** p < 0.01) of comparisons with the control at each time point. (B) Surface areas of neo-formed and 
pre-existing bone in the peri-implant space 3 and 6 weeks after implant placement (mean values ± SEM; n = 3 in 
each case). The asterisks denote the levels of statistical significance (* p < 0.05; ** p < 0.01) of comparisons with 
the control at each time point.
Fig. 9. Thickness of bone. (A) Thickness of the bony trabeculae in the porous space of the titanium mesh, (B) 
thickness of the trabeculae of neo-formed bone in the peri-implant space and (C) thickness of the trabeculae of pre-
existing bone in the peri-implant space 3 and 6 weeks after implant placement (mean ± SEM; n = 3 in each case). The 
asterisks denote the level of statistical significance (** p < 0.01) of comparisons with the control at each time point.
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value were thus 44.1 ± 2.6 % and 38.0 ± 4.4 %, respectively 
(Table 4).
 At the 6-week juncture, the direct BIC constituted a 
higher proportion of the total BIC than it did at 3 weeks 
(Fig. 10) – a finding that reflects the lower residual volumes 
of the coatings, which had undergone further degradation 
during the intervening period. This process of coating 
degradation had advanced to the greatest degree at the 
highest BMP-2 concentration (500 µg/g of coating). At 
this dosage, the residual coating volumes at the 3- and 6- 
week junctures were 2.4 ± 0.5 mm3 and 0.08 ± 0.08 mm3, 
respectively (Fig. 4); the corresponding indirect BICs were 
4.1 ± 3.1 mm2 and 1.8 ± 1.8 mm2, respectively (Fig. 10).
Net BMP-2 efficacy as appertaining to the bone 
surface area in the porous space of the titanium mesh
With respect to bone surface area, an inverse relationship 
between BMP-2 efficacy and BMP-2 concentration 
was clearly identifiable (Fig. 11, Table 5). A reduction 
in bone surface area was observed only at the highest 
BMP-2 concentration (500 µg/g of coating) at the 3-week 
juncture (−17.2 ± 4.5 mm2/d) (Table 5). At the lowest 
BMP-2 concentration (0.8 µg/g of coating), the BMP-
2 efficacy at the 3-week juncture was 31.8-fold higher 
than that at the 5-fold higher dosage (4 µg/g of coating) 
(46639.5 ± 3823.2 mm2/d vs. 1468.6 ± 1639.3 mm2/d). At 
the 6-week juncture, the BMP-2 efficacy was still 10.2-
fold higher at the lowest dosage of the agent (0.8 µg/g of 
coating) than at the 5-fold higher one (4 µg/g of coating) 
(26433.5 ± 2154.3 mm2/d vs. 2582.0 ± 1034.3 mm2/d). 
At the three yet higher BMP-2 concentrations (20, 100 
and 500 µg/g of coating), the two 5-fold-step increases 
in dosage (viz., between 20 and 100 µg/g of coating, and 
between 100 and 500 µg/g of coating), yielded BMP-2 
efficacy increases ranging from 1.25-fold to 10.1-fold at 
both time points. The average increase in BMP-2-efficacy 
over the 6-week monitoring period was 9.5-fold. If the 
values at the lowest dosage of BMP-2 were excluded, then 
the average increase in BMP-2 efficacy per 5-fold-step 
increase in BMP-2 concentration for the 6-week period 
was 5.7-fold, viz., the parameter was almost halved.
Bone volume in the deeper half of the porous space of 
the titanium mesh
In the deeper half of the porous space of the titanium mesh, 
the bone volume differed from that in the total porous space 
Fig. 10. Total area of the titanium surface that was 
covered either directly or indirectly (intervening layer 
of coating) with bone (BIC) 3 and 6 weeks after implant 
placement (mean values ± SEM; n = 3 in each case). 
The asterisks denote the level of statistical significance 
(** p < 0.01) of comparisons of total (direct plus 
indirect) BIC with the control at each time point.
Fig. 11. Net efficacy of BMP-2 – as appertaining to 
the surface area of bone in the porous space of the 
titanium mesh – 3 and 6 weeks after implant placement, 
represented on a decadal logarithmic scale. Negative 
values (500 µg of BMP-2/g of coating at 3 weeks) cannot 
be depicted on this scale [mean values ± SEM; n = 3 in 
each case. Correlation coefficients (ρ): ρ 3w = ˗ 0.76; ρ 
6w = ˗ 0.38].
BMP-2-concentration group
(µg/g of coating)
BIC (%)
3 weeks 6 weeks
0 (control) 11.2 ± 0.9 15.0 ± 2.3
0.8 44.1 ± 2.6 62.6 ± 3.5
4 21.6 ± 4.0 45.0 ± 9.3
20 38.0 ± 4.4 58.8 ± 6.3
100 21.1 ± 6.1 45.0 ± 3.7
500 0.8 ± 0.4 14.1 ± 1.8
Table 4. Percentage of the total surface area of the titanium 
implants that were covered either directly or indirectly 
(intervening layer of coating) with bone (BIC), 3 and 6 
weeks after implant placement. Values presented as mean 
values ± SEM; n = 3 in each case.
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Table 5. Net efficacy of BMP-2: Dose-dependency as appertaining to the surface 
area of bone in the porous space of the titanium mesh, 3 and 6 weeks after implant 
placement. Mean values ± SEM; n = 3 in each case.
BMP-2-concentration group
(µg/g of coating)
Surface area of bone (mm2/µg of BMP-2)
3 weeks 6 weeks
0.8 46639.5 ± 3823.2 26433.5 ± 2154.3
4 1468.6 ± 1,639.3 2582.0 ± 1034.3
20 1172.2 ± 281.4 1042.1 ± 190.8
100 116.0 ± 33.2 191.5 ± 24.5
500 −17.2 ± 4.5 24.0 ± 3.4
Fig. 12. Volumes of neo-formed bone in the deeper half of the porous space of the titanium mesh. (A) Absolute 
volumes of neo-formed bone in the deeper half of the porous space of the titanium mesh 3 and 6 weeks after implant 
placement (mean values ± SEM; n = 3 in each case). The asterisks denote the levels of statistical significance (* p < 0.05; 
** p < 0.01) of comparisons with the control at each time point. (B) Volume of bone in the deeper half of the porous 
space of the titanium mesh, expressed as a fraction (percentage) of that in the total porous space [deeper (inner) and 
outer halves], 3 and 6 weeks after implant placement (mean ± SEM; n = 3 in each case). The asterisks denote the levels 
of statistical significance (* p < 0.05; ** p < 0.01) of comparisons with the control at each time point.
(Fig. 12A and Fig. 6A). The deposition of bone in the deeper 
half tended to be higher than in the controls at all BMP-
2 concentrations and at both time points. At the 3-week 
juncture, the differences attained statistical significance at 
BMP-2 concentrations of 0.8 µg/g of coating (p = 0.028), 
20 µg/g of coating (p = 0.001) and 100 µg/g of coating 
(p = 0.039). At the 6-week juncture, statistical significance 
was achieved at BMP-2 concentrations of 100 µg/g of 
coating (p = 0.005) and 500 µg/g of coating (p < 0.001).
 Bone-volume fractions in the deeper half of the porous 
space likewise tended to be higher than in the controls at all 
BMP-2-concentrations and at both time points (Fig. 12B). 
However, at the 3-week juncture, the differences attained 
statistical significance only at BMP-2 concentrations of 
20 µg/g of coating (p = 0.03) and 500 µg/g of coating 
(p = 0.008). At the 6-week juncture, on the other hand, 
the differences were statistically significant at all BMP-2 
concentrations.
 The proportion of the deeper half of the porous space 
that was filled with neo-formed bone in the controls was 
5.3 ± 0.8 % and 9.9 ± 3.0 % at the 3- and 6-week junctures, 
respectively. In the experimental groups, the values at the 
3-week juncture ranged from 22.9 ± 1.9 % (4 µg of BMP-
2/g of coating) to 39.5 ± 12.6 % (500 µg of BMP-2/g of 
coating); those at the 6-week one from 24.3 ± 1.4 % (4 µg 
of BMP-2/g of coating) to 40.3 ± 1.3 % (500 µg of BMP-
2/g of coating) (Fig. 12B).
 The use of BMP-2 was expected to be associated with 
an increase in the depth to which bone penetrated the 
porous space of the titanium mesh and thereby to have a 
positive influence on the osseointegration of the implant 
and the strength of its mechanical fixation. The findings 
for the net in-growth pattern and penetration depth of 
the neo-formed bone (values normalised to those in the 
controls) (Table 6) accord with these expectations.
Net BMP-2 efficacies as appertaining to neo-formed 
bone volume
As appertaining to the volume of neo-formed bone in 
the porous space of the titanium mesh, the net efficacy 
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Fig. 13. Efficacies of BMP-2. (A) Net efficacy of BMP-2 – as appertaining to the volume of bone in the total porous 
space of the titanium mesh – 3 and 6 weeks after implant placement, represented on a decadal logarithmic scale 
[mean values ± SEM; n = 3 in each case. Correlation coefficients (ρ): ρ 3w = ˗ 0.31; ρ 6w = 0.46]. (B) Net efficacy of 
BMP-2 – as appertaining to the volume of bone in the deeper half of the porous space of the titanium mesh – 3 and 6 
weeks after implant placement, represented on a decadal logarithmic scale [mean values ± SEM; n = 3 in each case. 
Correlation coefficients (ρ): ρ 3w = ˗ 0.37; ρ 6w = ˗ 0.39]. (C) Net efficacy of BMP-2 – as appertaining to the volume 
of neo-formed bone in the peri-implant space – 3 and 6 weeks after implant placement, represented on a decadal 
logarithmic scale [mean values ± SEM; n = 3 in each case. Correlation coefficients (ρ): ρ 3w = ˗ 0.37; ρ 6w = ˗ 0.53].
of BMP-2 was not linearly related to the concentration 
of the agent and the intra-group variation was fairly high 
(Fig. 13A) (ρ 3w = ˗ 0.31; ρ 6w = 0.46). With respect to the 
net volumes of neo-formed bone in the deeper half of the 
porous space of the titanium mesh, the net BMP-2 efficacy 
decreased with an increase in BMP-2 concentration at 
both time points (Fig. 13B), although the relationship was 
not linear (ρ 3w3w = ˗ 0.37; ρ 6w3w = ˗ 0.39). However, if the 
data appertaining to the lowest and the highest BMP-2 
concentrations were excluded, good correlations between 
the values at dosages of 4 and 100 µg/g of coating were 
disclosed (ρ 3w3w = ˗ 0.95; ρ 6w3w = ˗ 0.87). A similar picture 
was revealed for the net bone surface area, with but 
one anomaly (4 µg/g of coating at the 3-week juncture) 
(Fig. 11). The BMP-2 efficacy for the neo-formed bone 
volume in the peri-implant space likewise decreased 
with an increase in BMP-2 concentration (ρ 3w3w = ˗ 0.37; 
ρ 6w3w = ˗ 0.53) (Fig. 13C).
Discussion
To affect a mechanically stable and durable osseointegration 
of orthopaedic and dental implants, and thereby to 
guarantee their longevity without loosening, is an important 
therapeutic goal in clinical practice. The process can be 
facilitated by functionalising the surfaces of titanium 
prostheses with a calcium-phosphate (bone-matrix-like) 
layer into which the osteoinductive agent BMP-2 has been 
incorporated (Boyne and Jones, 2004; Liu et al., 2006). By 
virtue of this mode of delivery, BMP-2 is released gradually 
and steadily at a low-dose rate during the coating’s 
osteoclast-mediated degradation – not spontaneously 
and rapidly in a single high-dose burst (Bhakta et al., 
2013) – whereby the sustained local formation of bone is 
promoted (Liu et al., 2005a; Liu et al., 2007). However, 
BMP-2 is known to induce not only the formation, but 
also the resorption of bone, and at high concentrations, 
the equilibrium between the two processes is tipped very 
much in favour of the latter (Nakamura et al., 2009; 
Table 6. Net volumes of bone in the deeper half of the porous space of the titanium 
mesh 3 and 6 weeks after implant placement, and the fold-increase in this parameter 
between the BMP-2-concentration groups. Mean values ± SEM; n = 3 in each case.
BMP-2-concentration group
(µg/g of coating)
Net bone volume (mm3)
3 weeks 6 weeks
0 (control) 0 Fold-increase 0
0.8 11.1 ± 1.5 ×11 12.7 ± 2.5
4 7.8 ± 2.7 ×8 8.7 ± 5.3
20 18.6 ± 4.3 ×18 16.4 ± 3.2
100 10.4 ± 0.9 ×10 25.1 ± 2.8
500 1.3 ± 2.4 ×1 41.2 ± 6.8
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Nakamura et al., 2003). No investigation has as yet been 
undertaken in vivo to determine the dosage window within 
which osteoinduction is maximised and bone resorption 
minimalised. The aim of the present study was to clarify 
this issue, to which end, porous titanium implants bearing 
different calcium-phosphate-coating-incorporated dosages 
of BMP-2 were inserted into the tibial bone of adult sheep. 
Various stereological estimators that are of relevance to the 
issue at stake were histomorphometrically evaluated 3 and 
6 weeks after surgery.
Coating degradation and BMP-2 release
The degree to which the implant coating had been degraded 
by the 3rd postoperative week (Fig. 4), which governed the 
amount of BMP-2 that was released (Fig. 5A), increased 
in parallel with the concentration of the osteoinductive 
agent. The dose-dependent increase in the rate of coating 
degradation (Fig. 5B) can be accounted for by the likewise 
dose-dependent induction of osteoclast formation and a 
concomitant augmentation of osteoclast-mediated coating 
degradation activity. By the 6th postoperative week, 
the situation had stabilised (Fig. 4), insofar as the total 
amount of degraded coating was somewhat lower than at 
the 3-week juncture. This finding implies that the daily 
rate of coating degradation was lower at the later than at 
the earlier time point. To account for this observation, we 
need to look no further than at the healing of a fractured 
or a lesioned bone in nature. This process involves a 
sequence of temporally defined events, which begins 
with the osteolysis of fragments of pre-existing bone 
(analogous to the osteoclast-mediated degradation of the 
coating during the first 3 postoperative weeks) (Lissenberg-
Thunnissen et al.,2011; Noda et al., 2009; Schell et al., 
2006). Later (after 3 weeks), bone-formative activity 
outweighs osteolytic activity (analogous to the slower rate 
of osteoclast-mediated coating degradation between the 3rd 
and the 6th postoperative weeks). The natural osteolytic 
process, as well as the rate of coating degradation, will be 
influenced by the local availability of BMP-2, which will 
be governed by the agent’s osteoclast-mediated liberation 
from a likewise local source – the indigenous bone matrix 
or the coating – during the material’s osteoclast-mediated 
degradation and potentiated at high local concentrations 
of the agent. At the highest BMP-2 concentration, no 
coating remained at the 6-week juncture (Fig. 4), a finding 
that is indicative of a BMP-2-overdose situation. At all 
other BMP-2 concentrations (0.8 to 100 µg/g of coating), 
residual coating material remained at this later time point. 
BMP-2 is trapped within this residual coating material 
and serves as a reserve for the continued stimulation of 
bone formation activity and the long-term consolidation 
of osseointegration. If the coating has undergone complete 
degradation by the 6th postoperative week, then the depot 
of BMP-2 will have been exhausted and the process of 
osseointegration arrested.
 When BMP-2 is available in a free form, which is the 
case if it is adsorbed onto the surface of a titanium implant, 
then it is liberated rapidly in a single high-dose burst, which 
promotes osteolysis (Nakamura et al., 2009; Nakamura 
et al., 2003). In clinical practice, this mode of BMP-2 
delivery was hitherto (McClellan et al., 2006; Saigal et al., 
2012; Singh et al., 2013), and still is, the norm (Faundez 
et al., 2016). A coating of calcium phosphate is in itself 
osteoconductive (Liu et al., 2007; Wong et al., 1995), but 
not osteoinductive (Liu et al., 2007). This attribute can be 
conferred only by an osteogenic agent, such as BMP-2. A 
calcium-phosphate coating into which BMP-2 has been 
biomimetically incorporated thus serves a dual function: 
it acts as an osteoconductive layer and as a vehicle for the 
slow, sustained delivery of the osteoinductive agent at low 
doses (Figs. 5A, B).
Bone volumes
Within the range of BMP-2 concentrations (0.8 to 500 µg/g 
of coating) that was tested in our model, the net volume of 
neo-formed bone did not differ significantly from that in 
the control, either in the porous space of the titanium mesh 
or in the peri-implant space, and at neither the 3- nor the 
6-week juncture, with but one anomaly (Figs. 6A, B). At 
the highest concentration of BMP-2 (500 µg/g of coating), 
the net volume of neo-formed bone in the porous space 
was considerably lower than that in the other experimental 
groups and in the control at the 3-week juncture, whereas 
at the 6-week one, the value was the highest of all. This 
pattern of osteogenesis points to a gross imbalance 
between bone formation and resorption, with the latter 
greatly outweighing the former at the earlier time point 
– a phenomenon that reflects the high rate of release of 
BMP-2 from the coating during the initial postoperative 
phase, as explained in the previous section. In clinical 
practice, a situation such as this is to be avoided, especially 
in patients suffering from osteoporosis, since the risk of 
implant dislocation, early loosening and even pathological 
fracturing would be greatly heightened. Likewise at the 
highest concentration of BMP-2 (500 µg/g of coating), the 
net volume of total bone (pre-existing and neo-formed) in 
the peri-implant space did not differ significantly from that 
in the control at either of the two time points (Fig. 6B).
Bone surface areas and BIC
BMP-2 enhanced the total surface area of bone in the 
porous space of the titanium mesh relative to that in 
the control at all concentrations and at both time points, 
with but one anomaly (Fig. 8A). At the highest BMP-2 
concentration (500 µg/g of coating), the total surface area 
of bone in the porous space – like the net volume – was 
significantly lower than that in the control at the 3-week 
juncture. But in contrast to the finding for net bone volume, 
the value for total bone surface area at the 6-week juncture 
was not higher than, but comparable to, those at the other 
BMP-2 concentrations. An explanation for the anomalous 
results at the highest dosage of BMP-2 is furnished under 
“Coating degradation and BMP-2 release”.
 In the porous space, the increase in the total surface area 
of bone relative to that in the control at the 3-week juncture 
attained statistical significance at BMP-2 concentrations 
of 0.8 and 20 µg/g of coating (Fig. 8A). At the 6-week 
juncture, the increases relative to the control value were 
statistically significant at all BMP-2 concentrations except 
at 4 µg/g of coating. A detailed inspection of the data for 
the individual implants in the latter case revealed the 
existence of outliers in the estimations of bone volume 
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and bone surface area. This circumstance is reflected in 
the high standard errors of the mean (Fig. 6A and Fig. 8A, 
respectively). The high coefficients of variation, combined 
with the low n-value (= 3), can readily lead to statistical 
non-significance in a comparison of data between groups.
 That the surface area but not the volume of neo-formed 
bone increased in the porous space reflects the presence 
of the osteoconductive and osteoinductive coating. An 
inspection of the histological images revealed neo-formed 
bone to be preferentially deposited along the surface of 
the coating-lined pores, not within the “empty” porous 
space itself (Figs 2A, B). Hence, the presence of the 
BMP-2-functionalised coating changed the pattern of bone 
formation in the porous space of the titanium mesh relative 
to that in the control. This change led to an increase in 
the (indirect) BIC (Fig. 10), which would have optimised 
the osseointegration of the implant. Although the highest 
BIC-values were attained at BMP-2 concentrations of 0.8 
and 20 µg/g of coating at both time points, increases in this 
parameter were achieved at all dosages below 500 µg/g of 
coating, viz., between 0.8 and 100 µg/g of coating.
 In the peri-implant space, the total surface area of neo-
formed and pre-existing bone did not differ markedly from 
that in the control at the end of the 6-week monitoring 
period (Fig. 8B). Only during the first 3 weeks did the 
surface area of neo-formed bone increase relative to that 
in the control, but even then only at BMP-2 concentrations 
of between 0.8 and 20 µg/g of coating (Fig. 8B). From 
the end-point results, it can be inferred that the domain of 
influence of BMP-2 was confined to the porous space of 
the titanium mesh during the 3rd to the 6th postoperative 
weeks at low dosages of the agent. The daily rate of release 
of BMP-2 was higher during the initial 3 weeks than during 
the 3rd to the 6th weeks (Fig. 5A, B), and the higher local 
levels of the agent that were thereby generated during this 
early phase relative to those that were produced during the 
latter one, probably influenced the pattern of neo-bone 
formation along the coating-lined surface of the pores.
 Given that the surface area of neo-formed bone in the 
porous space increased without a concomitant increase in 
its volume, the mean thickness of the trabeculae therein 
decreased significantly relative to that in the control at all 
BMP-2 concentrations and at both time points, with but 
one anomaly (500 µg/g of coating at the 6-week juncture) 
(Fig. 9). In the peri-implant space, the mean thickness of the 
trabeculae of neo-formed bone did not differ significantly 
from that in the control at any of the BMP-2 concentrations 
and at neither of the two time points. The mean thickness of 
the trabeculae of pre-existing bone tendentially decreased 
relative to that in the control during the first 3 weeks of 
monitoring at all BMP-2 concentrations, although the 
differences attained statistical significance only at 4 and 
500 µg/g of coating. During the 3rd to the 6th weeks, the 
mean thickness of the trabeculae of pre-existing bone 
did not differ significantly from that in the control at 
any of the BMP-2 concentrations. At the highest BMP-2 
concentration (500 µg/g of coating), the mean thickness 
of the trabeculae of pre-existing bone during the initial 
resorption phase was not compensated for by the deposition 
of neo-formed bone during the later one. Hence, by the end 
of the 6th week, the mean value for this parameter was 
tendentially lower at the highest than at the lower dosages 
of the agent (Figs 9B, C).
BMP-2 Efficacy
As appertaining to the total volume of neo-formed bone 
in the porous space of the titanium mesh, no clear dose-
dependent trend was identifiable on a linear scale. Albeit 
so, at the highest concentration of the agent (500 µg/g of 
coating), the BMP-2 efficacy tended towards zero.
 As aforementioned, BMP-2 had a clear influence on the 
pattern of bone formation along the coating-lined surface of 
the pores in the titanium mesh. And this influence was also 
apparent in the net efficacy of the agent, which increased 
with a decrease in BMP-2 concentration (Fig. 11). If the 
data appertaining to the lowest dosage were excluded, then 
for each 5-fold-step increase in BMP-2 concentration, the 
net efficacy of the agent decreased with a reciprocation 
factor of almost 5.7-fold during the 6-week monitoring 
period. If the data appertaining to the lowest BMP-2 
concentration were included, then the corresponding 
decrease in the efficacy of the agent was 9.5-fold. These 
calculations reveal the efficacy of the lowest concentration 
of BMP-2 (0.8 µg/g of coating) to greatly exceed that of 
the 5-fold-higher one (4 µg/g of coating). We therefore 
surmise that the tipping point in the equilibrium between 
bone formation and bone resorption probably occurs at 
a BMP-2 concentration of about 4 µg/g of coating. The 
critical BMP-2 concentration range within which bone 
resorption grossly outweighs bone formation lies between 
100 and 500 µg/g of coating in the present study (and 
above: see Materials and Methods section under “BMP-2 
concentrations”).
Conclusions
The presence of a BMP-2-functionalised calcium-
phosphate coating clearly increased the penetration depth 
at which neo-formed bone was deposited in the porous 
space of the titanium mesh during the 6-week monitoring 
period. In the control, approximately 5 % of the porous 
space was penetrated in the deeper half of the porous 
space during the first 3 postoperative weeks, which rose 
to 10 % during the 3rd to the 6th weeks. In the presence of 
a BMP-2-funtionalised coating, the corresponding values 
were, on average, 30 % and 31 %, respectively. The mean 
increase of 20 to 25 % in the bony in-growth depth and 
the higher BIC-values indicate that the osseointegration of 
the implants was enhanced in the presence of a BMP-2-
functionalised coating. As appertaining to the deposition 
of neo-formed bone in the deeper half of the porous space, 
the efficacy of BMP-2 was high at all concentrations of the 
agent between 0.8 and 100 µg/g of coating at both time 
points. Hence, bone resorption activity was lower in the 
deeper (inner) than in the outer half of the porous space.
 An optimally balanced osseointegrative effect was 
observed to occur at a BMP-2 concentration of 100 µg/g of 
coating. The neo-formation of bone during the first 3 weeks 
was moderate but still higher than that in the control, and 
the process was sustained during the 3rd to the 6th weeks 
at a higher level than at lower concentrations of the agent. 
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The mean gains in bone volume between the 3rd and the 
6th weeks were 20.9 mm3 (at 100 µg/g of coating) and 
6.3 mm3 (at < 100 µg/g of coating), respectively. These 
findings indicate that the titanium implants were optimally 
osseointegrated in this model at BMP-2 concentrations of 
between 20 and 100 µg/g of coating, with a maximisation 
of the effect at a dosage of 100 µg/g of coating.
 The findings of the present study revealed also that low 
concentrations of BMP-2 (≤ 100 µg/g of coating) exerted a 
positive influence on the bone surface area and the BIC, as 
well as on the structural pattern of bone formation. The BMP-
2-concentration window for maximum osseointegration 
was broad, lying between 20 and 100 µg/g of coating. This 
dosage range lies well below the concentrations of BMP-
2 that are contained within commercial products, such 
as Infuse Bone Grafts (Medtronic). In this latter device, 
the BMP-2 concentrations range between 1.05 mg/ACS 
(1.25 cm × 5 cm) and 12 mg/ACS (7.5 cm × 10 cm) (www. 
medtronic.com, www.infusebonegraft.com). The use of 
our BMP-2-functionalised calcium-phosphate coating in 
clinical practice – optimised dosage-wise in the light of the 
findings of the present study – would permit a tremendous 
reduction in the local concentration of the agent, which 
would improve the efficacy of bone formation, enhance 
implant osseointegration, reduce the risk of triggering 
untoward side effects and lessen the costs of surgery.
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Discussion with Reviewer
Christopher Evans: This study lacks of a control group 
of animals in which the titanium was coated with calcium 
phosphate lacking BMP-2.What is the authors’ reason 
behind this choice?
Authors: The purpose of the study was to elucidate 
the optimal BMP-2-dosage range that was needed for 
osteoinduction and for the osseointegration of the titanium 
mesh in vivo. Its aim was not to ascertain whether a coating 
of calcium phosphate alone, as an osteoconductive layer, 
would yield sufficient or comparable results. Moreover, this 
very issue was the subject of a previous study (Liu Y et al., 
2007), which revealed a coating of calcium phosphate to be 
highly osteoconductive – as evidenced by high BIC-values 
– but, as expected, not osteoinductive. In a subsequent 
investigation, only experimental dental implants that bore 
a coating-incorporated depot of BMP-2 underwent rapid 
osseointegration; those that bore a coating alone or no 
coating at all did not (Hunziker et al., 2012).
Christopher Evans: No mechanical testing – e.g. pull-out 
strength – has been performed on the implants.
Authors: No such experiments were undertaken since it 
was not the purpose of the study to test the mechanical 
strength of the osseointegrated implants. An analysis of 
this kind would have made sense only if the implant model 
had borne a resemblance in size and shape to the prosthesis 
that would be applied in human patients. Moreover, such 
a study would entail an inclusion of all the appropriate 
negative control groups, as well as the instrumentation of 
more discriminative time points.
Christopher Evans: Fig. 6 suggests that BMP-2 induces 
no new bone formation at any time point. Likewise, Fig. 
8B suggests that the amount of new bone found in the 
peri-implant space falls at 6 weeks.
Authors: Fig. 8B illustrates the surface area of bone in 
the peri-implant space – not the amount of bone. As the 
reviewer correctly points out, the surface area of bone was 
lower at 6 than at 3 weeks. But this circumstance does not 
imply that the bone volume was likewise lower at 6 weeks. 
The authors assume that the increase in the mean thickness 
of the trabecular bone at 6 weeks had a bearing on the 
decrease in the surface area of bone (Fig. 9B).
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